Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

383.70USD
19 Sep 2018
Change (% chg)

-- (--)
Prev Close
$383.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
293,332
52-wk High
$477.00
52-wk Low
$281.89

Chart for

About

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have... (more)

Overall

Beta: 1.13
Market Cap(Mil.): $40,727.84
Shares Outstanding(Mil.): 106.14
Dividend: --
Yield (%): --

Financials

  REGN.OQ Industry Sector
P/E (TTM): 23.10 108.51 32.45
EPS (TTM): 16.61 -- --
ROI: 24.43 1.61 12.63
ROE: 30.18 0.35 14.80

Sanofi pledges to keep up its restructuring efforts

(This version of the Sept. 14th story has been refiled to add dropped words in fifth paragraph)

Sep 18 2018

REFILE-UPDATE 1-Sanofi pledges to keep up its restructuring efforts

PARIS, Sept 14 Sanofi will continue to implement cost savings after having reached a 1.5 billion euros ($1.75 billion) cost reduction target a year ahead of expectations, and added that several of its key drugs were selling well.

Sep 18 2018

Factbox: Challenges facing German pharmaceutical company Bayer

FRANKFURT Bayer is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November, a person familiar with the company told Reuters.

Sep 04 2018

Regeneron's anti-blindness drug approved for less frequent treatments

Aug 17 Regeneron said on Friday it had won U.S. Food and Drug Administration approval for less-frequent applications of its Eylea anti-blindness treatment, which may come under pressure from a rival product made by Novatis

Aug 17 2018

Regeneron to invest $100 million in bluebird, jointly develop cancer therapies

Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer.

Aug 06 2018

Regeneron posts quarterly profit beat, strongly backs Eylea's future

Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit on Thursday, helped by higher sales of its newer medicines and outlined a growth strategy for its flagship drug Eylea, which is facing heightened competition.

Aug 02 2018

Regeneron profit beats expectations on sales of eczema drug

Aug 2 Drugmaker Regeneron Pharmaceuticals Inc reported a better-than-expected quarterly profit, helped by higher sales of eczema drug Dupixent.

Aug 02 2018

Sanofi says on track to regain solid position in cancer drugs

PARIS Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.

Jun 13 2018

UPDATE 1-Sanofi says on track to regain solid position in cancer drugs

PARIS, June 13 Sanofi believes it can make a comeback and re-establish a leading position in the competitive cancer drug market on the back of its immunotherapy drugs and efforts in new areas such as molecular oncology.

Jun 13 2018

Regeneron's newer drugs disappoint, shares slip

Regeneron Pharmaceuticals Inc disappointed Wall Street with lower-than-expected sales of its newer treatments, eczema medicine Dupixent and heart drug Praluent, exacerbating concerns over the company's future sales growth as its best-selling eye drug Eylea faces more competition.

May 03 2018

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF81.78 +0.04
Pfizer Inc. (PFE.N) $43.26 -0.25
Bayer AG (BAYGn.DE) €75.06 +1.03
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €74.58 -0.54
Merck & Co., Inc. (MRK.N) $69.98 -0.44
Amgen, Inc. (AMGN.OQ) $203.20 --
Roche Holding Ltd. (ROG.S) CHF235.85 -0.65
Roche Holding Ltd. (RO.S) CHF237.80 -0.80
Eli Lilly And Co (LLY.N) $105.74 -1.14

Earnings vs. Estimates